Factors Associated with Neurodevelopmental Retardation in Preterm Infants: A Single-center Experience

Preterm Bebeklerde Nörogelişimsel Gerilik ile İlişkili Faktörler: Tek Merkez Deneyimi

Rüya ÇOLAK¹ Meltem KIVILCIM² Senem ALKAN ÖZDEMİR³ Ezgi YANGIN ERGON³ Şebnem ÇALKAVUR³ Tülin GÖKMEN YILDIRIM³

¹istanbul Beykent University Faculty of Medicine, Department of Pediatrics, Clinic of Neonatal Intensive Care, İstanbul, Turkey ²University of Health Sciences Turkey, Dr. Behçet Uz Child Disease and Surgery Training and Research Hospital, Clinic of Developmental Behavioral Pediatrics, İzmir, Turkey

³University of Health Sciences Turkey, Dr. Behçet Uz Child Disease and Surgery Training and Research Hospital, Clinic of Neonatal Intensive Care, İzmir, Turkey

Cite as: Çolak R, Kıvılcım M, Alkan Özdemir S, Yangın Ergon E, Çalkavur Ş, Gökmen Yıldırım T. Factors Associated with Neurodevelopmental Retardation in Preterm Infants: A Single-center Experience. Forbes J Med 2022;3(3):297-302

ABSTRACT

Objective: Today, the survival rate of low-birth-weight infants has increased thanks to supportive care. However, various permanent health problems, especially neurodevelopmental retardation, can be seen in these infants. This study investigates the risk factors associated with neurodevelopmental retardation, especially hypocarbia, in this patient group.

Methods: All patients who were hospitalized in our neonatal intensive care unit between January 1 and December 31, 2016, with a gestational age of less than 32 weeks, without congenital anomalies, and who came for regular follow-up were included in this study. Demographic, clinical and laboratory data were obtained retrospectively from file records. The neurodevelopment of the patients was evaluated between 18 and 24 months with the Bayley Scales of Infants and Toddler Development, Second Edition (Bayley-II).The demographic, clinical and laboratory parameters of the patients with and without neurodevelopmental retardation were compared.

Results: Neurodevelopmental retardation was observed in 9 (16.1%) of the 56 patients included in the study. No neurodevelopmental retardation was detected due to cerebral palsy, hearing impairment or visual impairment. When the patient groups with and without neurodevelopmental retardation were compared in terms of demographic, clinical and laboratory parameters, birth weight and first and fifth-minute Apgar scores were lower in patients with neurodevelopmental retardation, while mechanical ventilation requirement, reintubation, convulsion, patent ductus arteriosus treatment, hypotension, bronchopulmonary dysplasia, asphyxia, hyperglycemia and hypocarbia rate were higher (p<0.05).

Conclusion: While providing mechanical ventilation support, in addition to the negative effects of hypercarbia on neurodevelopment, the negative effects of hypocarbia on neurodevelopment should also be kept in mind.

Keywords: Bayley Scale, hypocarbia, infant, neurodevelopmental retardation, preterm

ÖZ

Amaç: Günümüzde yenidoğan bakımındaki gelişmeler sayesinde düşük doğum ağırlıklı bebeklerin hayatta kalma oranları artmıştır. Ancak bu bebeklerde başta nörogelişimsel gerilik olmak üzere çeşitli kalıcı sağlık sorunları görülebilmektedir. Bu çalışma, bu hasta grubunda başta hipokarbi olmak üzere nörogelişimsel gerilik ile ilişkili risk faktörlerini araştırmayı amaçlamaktadır.

Yöntem: 1 Ocak-31 Aralık 2016 tarihleri arasında yenidoğan yoğun bakım ünitemizde yatan, 32 haftadan küçük, doğumsal anomalisi olmayan ve düzenli takibe gelen tüm hastalar bu çalışmaya dahil edildi.

[©]Telif Hakkı 2022 İzmir Buca Seyfi Demirsoy Eğitim ve Araştırma Hastanesi / Forbes Tıp Dergisi, Galenos Yayınevi tarafından yayınlanmıştır. Bu dergide yayınlanan bütün makaleler Creative Commons 4.0 Uluslararası Lisansı (CC-BY) ile lisanslanmıştır. Received/Gelis: 12.06.2022 Accepted/Kabul: 25.07.2022

Corresponding Author/ Sorumlu Yazar:

Rüya ÇOLAK MD,

İstanbul Beykent University Faculty of Medicine, Department of Pediatrics, Clinic of Neonatal Intensive Care, İstanbul, Turkey

Phone: +90 530 389 19 16

☑ ruyacolak@hotmail.comORCID: 0000-0002-8732-7932



[©]Copyright 2022 by the İzmir Buca Seyfi Demirsoy Training and Research Hospital / Forbes Journal of Medicine published by Galenos Publishing House. Licensed by Creative Commons Attribution 4.0 International (CC BY)

Demografik, klinik ve laboratuvar verileri dosya kayıtlarından geriye dönük olarak elde edildi. Hastaların nörogelişimleri 18-24 ay (düzeltilmiş yaş) arasında Bayley Scales of Infants and Toddler Development, Second Edition (Bayley-II) ile değerlendirildi. Nörogelişimsel geriliği olan ve olmayan hastaların demografik, klinik ve laboratuvar parametreleri karşılaştırıldı.

Bulgular: Çalışmaya alınan 56 hastanın 9'unda (%16,1) nörogelişimsel gerilik gözlendi. Serebral palsi, işitme veya görme bozukluğuna bağlı nörogelişimsel gerilik saptanmadı. Nörogelişimsel geriliği olan ve olmayan hasta grupları demografik, klinik ve laboratuvar parametreleri açısından karşılaştırıldığında, nörogelişimsel geriliği olan hastalarda doğum ağırlığı ve birinci ve beşinci dakika Apgar skorları daha düşük iken mekanik ventilasyon gereksinimi, yeniden entübasyon, konvülziyon, patent duktus arteriosus tedavisi, hipotansiyon, bronkopulmoner displazi, asfiksi, hiperglisemi ve hipokarbi oranı yüksekti (p<0,05).

Sonuç: Mekanik ventilasyon desteği sağlanırken hiperkarbinin nörogelişim üzerindeki olumsuz etkilerinin yanı sıra hipokarbinin nörogelişim üzerindeki olumsuz etkileri de akılda tutulmalıdır.

Anahtar Kelimeler: Bayley Skoru, hipokarbi, yenidoğan, nörogelişimsel gerilik, prematüre

INTRODUCTION

Infants born prematurely have lower survival rates compared to term infants. Additionally, a significant proportion of survivors must struggle with some health problems throughout their lives.^{1,2} In these infants in particular, intraventricular bleeding (IVB) and bronchopulmonary dysplasia (BPD) are common in the neonatal period, and neurodevelopmental retardation is common in later years.^{3,4} These health problems increase exponentially, especially in very low-birth-weight preterm infants.⁵ recently, survival rates have increased considerably with antenatal steroid treatment applied to the mothers of these patients before birth, surfactant treatment applied to infants after birth, and noninvasive mechanical ventilation support.⁶ However, some undesirable results may occur due to these supportive treatments. Periventricular leukomalacia due to hypocarbia seen during mechanical ventilation support due to respiratory distress is one of these results.7,8

Very low-birth-weight infants in particular should be followed up for neurodevelopment. Patients with neurodevelopmental retardation in the early period benefit more from early intervention due to the high incidence of cerebral plasticity cases in the early period of life. The Bayley Scales of Infants and Toddler Development, Second Edition (Bayley-II), which is frequently used to evaluate the neurodevelopment of preterm infants, consists of cognitive, language and motor parameters.^{9,10} In a study conducted in our country, it was reported that this scale has a sensitivity of 91% and a specificity of 49%.¹¹

In this study, it was aimed to determine the risk factors associated with neurodevelopmental retardation, especially hypocarbia, by evaluating the neuromotor development of infants with a gestational age <32 weeks and treated and followed in our neonatal intensive care unit at 18-24 months (corrected age) with the Bayley-II test.

METHODS

All patients, who were hospitalized in the Neonatal Intensive Care Unit of the Health Sciences University,

Dr. Behcet Uz Child Disease and Surgery Training and Research Hospital between January 1 and December 31, 2016, with a gestational age of less than 32 weeks, without congenital anomalies, and who came for regular followup were included in this study. Patients with congenital anomalies, without regular follow-ups, and where data were incomplete, were excluded from the study. The study was conducted with the approval of Dr. Behcet Uz Child Disease and Surgery Training and Research Hospital, dated 20.06.2019 and numbered 2019/300.

Demographic characteristics of patients such as antenatal steroid therapy, mode of delivery, gender, gestational age, birth weight, intrauterine growth retardation, clinical followup data such as the need for mechanical ventilation, Apgar score, Respiratory distress syndrome (RDS), surfactant therapy, phototherapy therapy, transfusion therapy, sepsis, apnea, presence of patent ductus arteriosus (PDA) requiring medical treatment, presence of convulsions, presence of hypotension requiring inotropes, necessity of reintubation, IVB, BPD and necrotizing enterocolitis (NEC) and laboratory findings such as C-reactive protein (CRP), hyperglycemia, hypocarbia, and asphyxia data were obtained retrospectively from the files of the patients.

A pCO_2 value of less than 40 mmHg in 2 consecutive capillary blood gases taken 6 h apart in the first 72 h after birth was considered hypocarbia. Low-birth-weight for age was defined as height or weight for age <-2 standard deviation (SD). Babies of mothers who received at least two doses of steroids at least 24 h before birth were considered to have received antenatal steroids.

The mental development index (MDI) and psychomotor development index (PDI) were measured by the developmental pediatrician with the Bayley Developmental Assessment Scale II for Infants, which was adapted to Turkish children at the age of 18-24 months (adjusted age). Additionally, all patients were examined by a pediatrician, and children with pathological neurological findings were evaluated by a pediatric neurologist. European guidelines were taken as reference for the diagnosis of cerebral palsy.¹² In the hearing and ophthalmological evaluations

made by otolaryngologists and ophthalmologists, the report of the British Society of Perinatal Medicine was taken as a reference for the definitions of vision and hearing disorders.¹³ The presence of any following criterion was accepted as an indicator of neurodevelopmental retardation: cerebral palsy, hearing impairment, visual impairment, MDI or PDI score <70.¹⁴

Statistical Analysis

The Statistical Package for the Social Sciences 25.0 (IBM Corporation, Armonk, New York, United States) program was used in the analysis of the variables. The conformity of data to a normal distribution was evaluated with the Shapiro-Wilk test and homogeneity of variance was evaluated with the Levene test. The independent-samples t-test was used together with the Bootstrap results, while the Mann-Whitney U test was used together with the Monte Carlo results in the comparison of two independent groups according to the quantitative data. The Jonckheere-Terpstra test with the results of the Monte Carlo simulation technique was used to compare more than two groups with each other according to the quantitative data. In the comparison of categorical variables with each other, the Pearson chi-squared and Fisher exact tests were used together with the exact results, while the Fisher-Freeman-Holton test was used together with the Monte Carlo Simulation technique. Quantitative variables were shown as mean±SD and median (minimum/maximum), and categorical variables as n (%). Variables were analyzed at 95% confidence level and the p value was considered significant when it was <0.05.

RESULTS

It was wished to include 74 patients in the study. However, only 56 patients could be included in the study, since 6 of them had died during the follow-up, 3 of them had congenital anomalies, and 9 of them did not come for regular control. Of the patients, 26 (46.4%) were male and the gestational age of 33 (58.9%) patients was 29-32 weeks, while 23 (41.1%) were <28 weeks. Ten (17.9%) patients were delivered by vaginal delivery and 46 (82.1%) of them were delivered by emergency cesarean section. Birth weight was <1000 g in 13 patients (23.2%), 1001-1500 g in 31 (55.4%) and more than 1500 g in 12 (21.4%) patients. Neurodevelopmental retardation was observed in 9 (16.1%) patients. Neurodevelopmental retardation was not detected in any patient due to cerebral palsy, hearing impairment or visual impairment. The general characteristics of the patients are summarized in Table 1.

Patient groups with and without neurodevelopmental retardation were compared in terms of demographic,

clinical and laboratory parameters. When the patients were compared in terms of demographic characteristics, the birth weight of the patients with neurodevelopmental retardation was lower (p<0.05).

ender (male) estational age (week) 9-32 28 ode of delivery 'aginal delivery mergency cesarean section irth-weight (g) 1000 001-1500 1500 ntenatal steroid therapy JGR pgar score 1st min* pgar score 5th min* lechanic ventilation CPAP ntubated DS ('H urfactant therapy pnea hototherapy epsis DA treatment (medical) cansfusion	n (%) 26 (46.4) 33 (58.9) 23 (41.1) 10 (17.9) 46 (82.1) 13 (23.2) 31 (55.4) 12 (21.4) 32 (80.0) 5 (8.9) 5.65±1.73 7.09±1.27 42 (75.0) 14 (25.0) 32 (57.1) 18 (32.1) 30 (53.6)
estational age (week) 9-32 28 lode of delivery imergency cesarean section irth-weight (g) 1000 001-1500 1500 ntenatal steroid therapy JGR pgar score 1 st min* pgar score 5 th min* echanic ventilation CPAP htubated DS //H urfactant therapy pnea hototherapy epsis DA treatment (medical)	33 (58.9) 23 (41.1) 10 (17.9) 46 (82.1) 13 (23.2) 31 (55.4) 12 (21.4) 32 (80.0) 5 (8.9) 5.65±1.73 7.09±1.27 42 (75.0) 14 (25.0) 32 (57.1) 18 (32.1)
9-32 28 lode of delivery (aginal delivery imergency cesarean section irth-weight (g) 1000 001-1500 1500 Intenatal steroid therapy JGR pgar score 1st min* pgar score 5th min* lechanic ventilation CPAP Intubated DS //H urfactant therapy pnea hototherapy epsis DA treatment (medical)	23 (41.1) 10 (17.9) 46 (82.1) 13 (23.2) 31 (55.4) 12 (21.4) 32 (80.0) 5 (8.9) 5.65±1.73 7.09±1.27 42 (75.0) 14 (25.0) 32 (57.1) 18 (32.1)
ode of delivery (aginal delivery imergency cesarean section irth-weight (g) 1000 001-1500 1500 ntenatal steroid therapy JGR pgar score 1st min* pgar score 5th min* lechanic ventilation CPAP ntubated DS //H urfactant therapy pnea hototherapy epsis DA treatment (medical)	10 (17.9) 46 (82.1) 13 (23.2) 31 (55.4) 12 (21.4) 32 (80.0) 5 (8.9) 5.65±1.73 7.09±1.27 42 (75.0) 14 (25.0) 32 (57.1) 18 (32.1)
faginal delivery imergency cesarean section irth-weight (g) 1000 001-1500 1500 ntenatal steroid therapy JGR pgar score 1st min* pgar score 5th min* lechanic ventilation CPAP ntubated DS //H urfactant therapy pnea hototherapy epsis DA treatment (medical)	46 (82.1) 13 (23.2) 31 (55.4) 12 (21.4) 32 (80.0) 5 (8.9) 5.65±1.73 7.09±1.27 42 (75.0) 14 (25.0) 32 (57.1) 18 (32.1)
1000 001-1500 1500 Itenatal steroid therapy JGR pgar score 1 st min* pgar score 5 th min* lechanic ventilation CPAP htubated DS //H urfactant therapy pnea hototherapy epsis DA treatment (medical)	31 (55.4) 12 (21.4) 32 (80.0) 5 (8.9) 5.65±1.73 7.09±1.27 42 (75.0) 14 (25.0) 32 (57.1) 18 (32.1)
001-1500 1500 ntenatal steroid therapy JGR pgar score 1 st min* pgar score 5 th min* lechanic ventilation CPAP ntubated DS /H urfactant therapy pnea hototherapy epsis DA treatment (medical)	31 (55.4) 12 (21.4) 32 (80.0) 5 (8.9) 5.65±1.73 7.09±1.27 42 (75.0) 14 (25.0) 32 (57.1) 18 (32.1)
JGR pgar score 1 st min* pgar score 5 th min* lechanic ventilation CPAP ntubated DS //H urfactant therapy pnea hototherapy epsis DA treatment (medical)	32 (80.0) 5 (8.9) 5.65±1.73 7.09±1.27 42 (75.0) 14 (25.0) 32 (57.1) 18 (32.1)
JGR pgar score 1 st min* pgar score 5 th min* lechanic ventilation CPAP ntubated DS //H urfactant therapy pnea hototherapy epsis DA treatment (medical)	5.65±1.73 7.09±1.27 42 (75.0) 14 (25.0) 32 (57.1) 18 (32.1)
pgar score 5 th min* lechanic ventilation CPAP htubated DS //H urfactant therapy pnea hototherapy epsis DA treatment (medical)	7.09±1.27 42 (75.0) 14 (25.0) 32 (57.1) 18 (32.1)
echanic ventilation CPAP htubated DS /H urfactant therapy pnea hototherapy epsis DA treatment (medical)	42 (75.0) 14 (25.0) 32 (57.1) 18 (32.1)
CPAP Intubated DS //H urfactant therapy pnea hototherapy epsis DA treatment (medical)	14 (25.0) 32 (57.1) 18 (32.1)
ntubated DS /H urfactant therapy pnea hototherapy epsis DA treatment (medical)	14 (25.0) 32 (57.1) 18 (32.1)
/H urfactant therapy pnea hototherapy epsis DA treatment (medical)	18 (32.1)
urfactant therapy pnea hototherapy epsis DA treatment (medical)	
pnea hototherapy epsis DA treatment (medical)	30 (53.6)
hototherapy epsis DA treatment (medical)	
epsis DA treatment (medical)	45 (80.4)
DA treatment (medical)	43 (76.8)
	35 (62.5)
ransfusion	16 (28.6)
	39 (69.6)
onvulsion	4 (7.3)
eintubation	11 (19.6)
PD	9 (16.1)
EC	1 (1.8)
ypotension	8 (14.3)
sphyxia	5 (8.9)
yperglycemia	5 (8.9)
ypocarbia	30 (53.6)
ayley MDI (<70)	5 (8.9)
ayley PDI (<70)	6 (10.7)
eurodevelopmental retardation	9 (16.1)

IUGR: Intrauterine growth retardation, RDS: Respiratory distress syndrome, IVH: Intraventricular hemorrhage, BPD: Bronchopulmonary dysplasia, NEC: Necrotizing enterocolitis, MDI: Mental development index, PDI: Psychomotor development index, PDA: Patent ductus arteriosus When a comparison was made in terms of clinical findings, the first and fifth-minute Apgar scores of patients with neurodevelopmental delay were found to be lower, while the rate of patients receiving mechanical ventilation support, the rate of patients undergoing reintubation, the rate of patients with convulsions, the rate of patients receiving medical treatment for PDA treatment, and the rate of patients requiring inotropic therapy and the rate of patients with hypotension and the rate of patients with BPD were statistically significantly higher (p<0.05). In terms of laboratory findings, the rate of patients who developed asphyxia, hyperglycemia and hypocapnia in the patient group with neurodevelopmental retardation was statistically higher (p<0.05). There was no difference between the two groups in terms of gender, gestational age, mode of delivery, intrauterine growth retardation, antenatal steroid treatment, surfactant treatment, phototherapy treatment, blood transfusion, sepsis, apnea, IVB, RDS and NEC parameters (p>0.05) (Table 2).

DISCUSSION

In this study, it was shown that the development of hypocarbia in the early period (within the first 72 h after birth) in infants with a gestational age of <32 weeks is a risk factor for neurodevelopmental retardation. Additionally, as previously reported in the literature, low birth-weight, low Apgar score, the need for mechanical ventilation, the need for reintubation, asphyxia, convulsion, hypotension, hyperglycemia, the presence of PDA requiring medical treatment, and BPD were also associated with neurodevelopmental retardation in the current study.

In the study by Bulbul et al.¹⁵, it was reported that cerebral palsy was seen in 11.5% of infants with a gestational age of <34 weeks, and when evaluated with the Bayley-III scale, 13% had cognitive retardation and 31% had neuromotor developmental retardation. In a meta-analysis by Pascal et al.¹⁶, however, when low or very lowbirth-weight infants were evaluated at the corrected age of 2 years, it was reported that neurodevelopmental retardation was found in approximately 20.6% of them. In a review study by Palumbi et al.¹⁷, it was reported that 32.4% of late preterm infants had retardation in language development. In the study by Agarwal et al.¹⁸, neurodevelopmental retardation was found at a rate of 20% in very low-birth-weight infants around 2 years of age. However, none of the patients included in the current study developed cerebral palsy, nor had hearing or visual impairments. Neurodevelopmental retardation was found in 16% of the patients, consistent with the literature.

It has been reported that periventricular leukomalacia develops in infants who develop hypocarbia with early mechanical ventilation support applied to very low-birthweight infants and who are exposed to hypocarbia for one hour.^{7,8} In a study by Murase and Ishida¹⁹, it was reported that periventricular leukomalacia developed due to hypocarbia in this group of patients, and cerebral palsy developed mostly in these patients in the follow-up. Thome et al.²⁰, however, reported that 16% of very low- birth-weight infants developed hypocarbia, and there was no difference

Table 2. Comparison of demographic, clinical and

laboratory findings of patients with and without

	Neurodevelopmental retardation		
	Absent (n=47)	Present (n=9)	þ
Gender (male)	22 (46.8)	4 (44.4)	0.999f
Gestational age (week)**	30 (24/32)	27 (24/32)	0.119 ^u
Birth-weight (g)*	1275±297	927±418	0.026 ^t
Mode of delivery (caesarean section), n (%)	39 (83)	7 (77.8)	0.999
IUGR	3 (6.4)	2 (22.2)	0.178 ^f
Antenatal steroid therapy, n (%)	27 (81.8)	5 (71.4)	0.336 ^{fh}
Apgar score** I st min 5 th min	6 (1/9) 8 (5/10)	5 (1/6) 7 (3/7)	0.003 ^u 0.006 ^u
Ventilator support	8 (17)	6 (66.7)	0.005 ^f
Surfactant therapy, n (%)	25 (53.2)	5 (55.6)	0.999f
Phototherapy, n (%)	34 (72.3)	9 (100.0)	0.098f
Transfusion, n (%)	32 (68.1)	7 (77.8)	0.707f
Sepsis, n (%)	28 (59.6)	7 (77.8)	0.459f
Convulsion, n (%)	0 (0.0)	4 (44.4)	<0.001
Hypotension, n (%)	4 (8.5)	4 (44.4)	0.017 ^f
Hyperglycemia, n (%)	3 (6.4)	3 (33.3)	0.046 ^f
Apnea, n (%)	28 (59.6)	2 (22.2)	0.066 ^f
Asphyxia	2 (4.3)	3 (33,3)	0.025 ^f
Reintubation	6 (12.8)	5 (55.6)	0.010 ^f
PDA closure, n (%)	10 (21.3)	6 (66.7)	0.012 ^f
Hypocarbia, n (%)	1 (3.8)	8 (26.7)	0.029 ^f
IVB, n (%)	13 (27.7)	5 (55.6)	0.129 ^f
RDS, n (%)	26 (55.3)	6 (66.7)	0.718 ^f
BPD, n (%)	3 (6.4)	6 (66.7)	<0.001
NEC, n (%)	1 (2.1)	0 (0.0)	0.999 ^f

^pPearson chi-squared test (exact), ^FFisher's exact test, ^{FH}Fisher-Freeman-Halton test (Monte Carlo), ^TIndependent samples t-test (Bootstrap), ^UMann-Whitney U test (Monte Carlo), ^WWilcoxon signedrank test (Monte Carlo).

**Median (minimum/maximum), *mean±standard deviation.

IUGR: Intrauterine growth retardation, RDS: Respiratory distress syndrome, IVB: Intraventricular bleeding, BPD: Bronchopulmonary dysplasia, NEK: Necrotizing enterocolitis, PDA: Patent ductus arteriosus

in neurodevelopment between patients with hypocarbia and normocarbic patients. In this study, it was determined that neurodevelopmental retardation was more common in infants who developed hypocarbia within the first 72 h after birth. To the best of our knowledge, no such data have been reported in the literature before.

Birth weight and gestational age play an important role in both survival and neurodevelopmental outcomes.²¹ Additionally, it has been reported that the duration of mechanical ventilation support has a negative effect on neurodevelopment in low and very low-birth-weight infants.¹ In a study by Bulbul et al.¹⁵, it was reported that birthweight, gestational age, Apgar score, duration of oxygen therapy, duration of mechanical ventilation support, and need for resuscitation in the delivery room were associated with neuromotor development retardation in infants with a gestational age of <34 weeks. In a study by Zambrana et al.²², however, an inverse correlation was reported between gestational age and cognitive retardation. Similar to the literature, low birth-weight, low Apgar score, asphyxia, the need for mechanical ventilation and the need for reintubation were associated with neurodevelopmental retardation in this study.

In a study by Asztalos et al.²³, BPD, NEC, and severe neurological damage were reported to be strongly associated with neurodevelopmental retardation. Similar to the literature, neurodevelopmental retardation was found to be more common in patients with BPD in the current study. However, no association was found between NEC and neurodevelopmental retardation. This is thought to be because we only had one patient who developed NEC.

In a study by Agarwal et al.¹⁸, it was reported that there is a relationship between non-administration of antenatal steroids to the mother, male gender, the presence of hypotension requiring inotropes and cognitive neurodevelopment retardation. Wong et al.²⁴, however, reported no relationship between antenatal steroid use and neurodevelopmental retardation. In a meta-analysis by Sotiriadis et al.²⁵, it was reported that the use of steroids even once during the antenatal period helps prevent the development of neurodevelopmental retardation. Similar to the literature, a relationship between the presence of hypotension requiring inotropes and neurodevelopmental retardation was demonstrated in the current study. However, there was no relationship between antenatal steroid use and neurodevelopmental retardation. This difference is thought to be due to the small number of patients included in the study.

Gonzalez Villamizar et al.²⁶ Reported that the neurodevelopment of infants with a gestational age of <32 weeks, who had hyperglycemia after birth, was lagged. Gudmundsdottir et al.²⁷, however, reported that PDA

increases the risk of neurodevelopmental retardation in very low-birth-weight infants, whether treated surgically or medically. In this study, in parallel with the literature, it was shown that there is a relationship between the presence of hyperglycemia in the neonatal period and the presence of PDA requiring medical treatment, and neurodevelopmental retardation.

Study Limitations

The study has some limitations. First, the findings cannot be generalized because the study was single-center. The second limitation is the small number of patients included in the study, while the third limitation is the retrospective nature of the study. It is thought that these limitations of the study will not change the results obtained.

CONCLUSION

In conclusion, currently, the rate of survival for low and very low-birth-weight infants is high thanks to supportive treatments such as antenatal steroid therapy, surfactant therapy, and mechanical ventilation support. However, a significant proportion of these patients have neurodevelopmental retardation compared to their peers. It is vital for normal neurodevelopment to protect those patients, who need respiratory support, especially in the early neonatal period, from hypocarbia and from hypercarbia.

Ethics

Ethics Committee Approval: The study was approved by the Dr. Behcet Uz Child Disease and Surgery Training and Research Hospital Local Ethics Committee (date: 23.05.2019, protocol no: 2019/300).

Informed Consent: Retrospective study.

Peer-review: Externally peer-reviewed.

Authorship Contributions

Concept: R.Ç., M.K., Ş.Ç., T.G.Y., Design: R.Ç., M.K., Ş.Ç., T.G.Y., Data Collection or Processing: R.Ç., S.A.Ö., Analysis, or Interpretation: R.Ç., E.Y.E., Literature Search: R.Ç., E.Y.E., Writing: R.Ç.

Conflict of Interest: No conflict of interest was declared by the authors.

Financial Disclosure: The authors declared that this study received no financial support.

REFERENCES

- 1. Do CHT, Kruse AY, Wills B, et al. Neurodevelopment at 2 years corrected age among Vietnamese preterm infants. Arch Dis Child. 2020;105:134-40.
- 2. Vohr BR. Neurodevelopmental outcomes of extremely preterm infants. Clin Perinatol. 2014;41:241-55.

- Twilhaar ES, Wade RM, de Kieviet JF, van Goudoever JB, van Elburg RM, Oosterlaan J. Cognitive Outcomes of Children Born Extremely or Very Preterm Since the 1990s and Associated Risk Factors: A Meta-analysis and Meta-regression. JAMA Pediatr. 2018;172:361-7.
- Guellec I, Lapillonne A, Marret S, et al. Effect of Intra- and Extrauterine Growth on Long-Term Neurologic Outcomes of Very Preterm Infants. J Pediatr. 2016;175:93-9.e1.
- McGowan EC, Vohr BR. Neurodevelopmental Follow-up of Preterm Infants: What Is New? Pediatr Clin North Am. 2019;66:509-23.
- 6. Horbar JD, Carpenter JH, Badger GJ, et al. Mortality and neonatal morbidity among infants 501 to 1500 grams from 2000 to 2009. Pediatrics. 2012;129:1019-26.
- Resch B, Neubauer K, Hofer N, et al. Episodes of hypocarbia and early-onset sepsis are risk factors for cystic periventricular leukomalacia in the preterm infant. Early Hum Dev. 2012;88:27-31.
- Hatzidaki E, Giahnakis E, Maraka S, et al. Risk factors for periventricular leukomalacia. Acta Obstet Gynecol Scand. 2009;88:110-5.
- Spencer-Smith MM, Spittle AJ, Lee KJ, Doyle LW, Anderson PJ. Bayley-III Cognitive and Language Scales in Preterm Children. Pediatrics. 2015;135:e1258-65.
- 10. Vohr BR, Stephens BE, Higgins RD, et al. Are outcomes of extremely preterm infants improving? Impact of Bayley assessment on outcomes. J Pediatr. 2012;161:222-8.e3.
- Saldir M, Sarici SU, Bakar EE, Ozcan O. Neurodevelopmental status of preterm newborns at infancy, born at a tertiary care center in Turkey. Am J Perinatol. 2010;27:121-8.
- 12. Surveillance of Cerebral Palsy in Europe. Surveillance of cerebral palsy in Europe: a collaboration of cerebral palsy surveys and registers. Surveillance of Cerebral Palsy in Europe (SCPE). Dev Med Child Neurol. 2000;42:816-24.
- 13. Report of a Bapm/Rcpch working group, Classification of Health Status at 2 Years as a Perinatal Outcome, BAPM, London, 2008.
- Rogers EE, Hintz SR. Early neurodevelopmental outcomes of extremely preterm infants. Semin Perinatol. 2016;40:497-509.
- Bulbul L, Elitok GK, Ayyıldız E, et al. Neuromotor Development Evaluation of Preterm Babies Less than 34 Weeks of Gestation with Bayley III at 18-24 Months. Biomed Res Int. 2020;2020:5480450.
- 16. Pascal A, Govaert P, Oostra A, Naulaers G, Ortibus E, Van den Broeck C. Neurodevelopmental outcome in very preterm and

very-low-birthweight infants born over the past decade: a meta-analytic review. Dev Med Child Neurol. 2018;60:342-55.

- 17. Palumbi R, Peschechera A, Margari M, et al. Neurodevelopmental and emotional-behavioral outcomes in late-preterm infants: an observational descriptive case study. BMC Pediatr. 2018;18:318.
- Agarwal PK, Shi L, Rajadurai VS, et al. Factors affecting neurodevelopmental outcome at 2 years in very preterm infants below 1250 grams: a prospective study. J Perinatol. 2018;38:1093-100.
- 19. Murase M, Ishida A. Early hypocarbia of preterm infants: its relationship to periventricular leukomalacia and cerebral palsy, and its perinatal risk factors. Acta Paediatr. 2005;94:85-91.
- Thome UH, Dreyhaupt J, Genzel-Boroviczeny O, et al. Influence of PCO2 Control on Clinical and Neurodevelopmental Outcomes of Extremely Low Birth Weight Infants. Neonatology. 2018;113:221-30.
- 21. Scheiner AP, Sexton ME. Prediction of developmental outcome using a perinatal risk inventory. Pediatrics. 1991;88:1135-43.
- 22. Zambrana IM, Vollrath ME, Sengpiel V, Jacobsson B, Ystrom E. Preterm delivery and risk for early language delays: a siblingcontrol cohort study. Int J Epidemiol. 2016;45:151-9.
- Asztalos EV, Church PT, Riley P, Fajardo C, Shah PS; Canadian Neonatal Network and Canadian Neonatal Follow-up Network Investigators. Neonatal Factors Associated with a Good Neurodevelopmental Outcome in Very Preterm Infants. Am J Perinatol. 2017;34:388-96.
- 24. Wong D, Abdel-Latif M, Kent A; NICUS Network. Antenatal steroid exposure and outcomes of very premature infants: a regional cohort study. Arch Dis Child Fetal Neonatal Ed. 2014;99:F12-20.
- Sotiriadis A, Tsiami A, Papatheodorou S, Baschat AA, Sarafidis K, Makrydimas G. Neurodevelopmental Outcome After a Single Course of Antenatal Steroids in Children Born Preterm: A Systematic Review and Meta-analysis. Obstet Gynecol. 2015;125:1385-96.
- Gonzalez Villamizar JD, Haapala JL, Scheurer JM, Rao R, Ramel SE. Relationships between Early Nutrition, Illness, and Later Outcomes among Infants Born Preterm with Hyperglycemia. J Pediatr. 2020;223:29-33.e2.
- 27. Gudmundsdottir A, Broström L, Skiöld B, et al. The type and timing of patent ductus arteriosus treatment was associated with neurodevelopment when extremely preterm infants reached 6.5 years. Acta Paediatr. 2021;110:510-20.